冰球突破

News

120191217153821

News

Innovative Drug Lieritinib Tablets (Aoyixin®) to Presented Long-T
2026-03-18
The 2026 European Lung Cancer Congress (ELCC 2026) will be held in Copenhagen, Denmark, from March 25 to 28 (local time). ELCC is one of the most influential international academic conferences in the ...
查看详情>
Molecular Glue Reshapes RAS Target Landscape: ASK Pharm and Adlai Nort
2025-12-29
Dec 29, 2025,ASK Pharm (SZ stock code: 002755) announced that it has signed a cooperation agreement with Adlai Nortye (NASDAQ stock code: ANL).ASK Pharm has obtained the exclusive rights to develop, m...
查看详情>
2025 ESMO | Latest Research Results of ASKB589 (CLDN18.2 mAb) Triple C
2025-10-27
On Oct 19, 2025, at the European Society for Medical Oncology (ESMO) Annual Congress in Berlin, Germany, AskGene Pharma Inc—a subsidiary of ASK Pharm—presented updated clinical data in a poster presen...
查看详情>
Subsidiary AskGene, Reaches License Agreement for Ophthalmic Innovativ
2025-10-27
On October 17, 2025, AskGene Pharma, Inc. (“AskGene”), a subsidiary of ASK, announced that it has entered into an exclusive licensing agreement with Visara, Inc. (“Visara”) for ASKG712, a Class 1 inno...
查看详情>
ASKC 202 Phase III Clinical Investigator Meeting Held Grandly in Nanji
2025-07-09
On July 6, 2025, the "More Precision × High Quality × Long-term Survival · Experts Discuss the Future Vision of MET+ and ASKC202 Tablet Phase III Clinical Investigator Meeting"...
查看详情>
ASK Honored as "Excellent Case of Chinese Pharmaceutical R&D
2025-07-08
From July 5-7, 2025, the 42nd China pharmaceutical Industrial Information Annual Conference and Beijing Changping Forum On Life Science were held in Changping, Beijing. Themed "Ignite Life For Fu...
查看详情>
ASK's Innovative Drug Lierutinib Tablets (Aoyixin®) Phase III
2025-06-23
June 23, 2025 – ASK (SZ Stock Symbol: 002755) announced that the Phase III clinical study results of its innovative drug, Lierutinib Tablets (Aoyixin®), have been published in the medical journal...
查看详情>
Embarking on a New Journey | Ask Pharma Selected for "Jiangsu Top
2024-12-05
Recently, the Jiangsu Federation of industry and Commerce released the "2024 Jiangsu Top 100 Private Enterprises" series of lists. Ask Pharm was successfully included in the "2024 Jiang...
查看详情>
The First Group | Ask Once Again Selected for "2024 Top 100 Chine
2024-12-04
Recently, the 16th China Healthcare Summit of Entrepreneurs, Scientists, and Investors (CHSESI) was grandly held in Chengdu. The conference was organized by the China Pharmaceutical Enterprise Managem...
查看详情>
Ask Pharm and Innovent Announce Strategic Collaboration for Limertinib
2024-10-08
SAN FRANCISCO, U.S., SUZHOU, China, Sept 30, 2024 —Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm, 002755.SZ), and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), a world-class biopharmaceu...
查看详情>

上一页12 ...下一页

联系冰球突破

综合事务

地址：漯河市江宁区江宁科学园科建路699号

电话：86-025-52169999

传真：86-025-52162777
扫码关注

冰球突破资讯

Copyright ? 2019 冰球突破版权所有苏ICP备09088815号-1 互联网药品信息服务资格证书编号：苏网药械信备字〔2025〕00121号企业邮箱 | OA

网站建设：龙媒网络

返回顶部

Copyright ?2019 江苏冰球突破有限公司

【网站地图】